X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Health & Nutrition

Innovative medical nutrition developed by Vitalnext aims to improve health of malnourished elderly and make their muscles stronger

Content Team by Content Team
2nd January 2018
in Health & Nutrition

It is the goal of Vitalnext that by taking a few portions per day of Vital01, an innovative nutrition for special medical purposes, undernourished elderly may faster regain body weight and experience improvement of muscle mass. The medical nutrition is developed by Vitalnext BV, a Wageningen based company.

It has the ambition to give older people worldwide a better quality of life and to significantly reduce healthcare costs. Partly by an investment from Topfonds Gelderland provided by ‘Participatie maatschappij East Netherlands’ (PPM Oost) Vitalnext expects to introduce Vital01 on the market next year.

Malnutrition amongst elderly is a growing problem, according to Rein Strijker CEO and founder of Vitalnext. He refers to a report of the Dutch National Health Council which shows that 25 percent of people over 65 is malnourished. ”Those people have no feeling of hunger, but their physical condition is worsening. Consequently, they will move around less. Yet ,it is the combination of nutrition and exercise that will reduce the breakdown of muscles and support building muscles.” The decrease in muscle mass means less power and a decline in immune function. This might lead to a vicious cycle when, for example, an elderly person falls and breaks a hip. “The physical condition will worsen even faster when this person is in a poor nutritional status ” says Strijker.

Increasing healthcare costs
Malnutrition not only has medical consequences for the elderly, it also increases healthcare costs considerably. Strijker: “Malnourished elderly get sick more often and recover more slowly. Thus, hospital or nursing home stays are more frequent and last longer in the elderly population. The increasing life expectancy means that these costs will grow substantially.” The additional hospital costs for malnutrition in Netherlands are estimated at € 1.1 billion and the additional cost of nursing and care homes more than € 500 million. “And worldwide the Netherlands is even a small market,” says Strijker.

Powder formula
Several large nutrition companies have products (in small bottles) against malnutrition on the market. Vital01 also contains all necessary vitamins, minerals and other nutrients to combat malnutrition. However, Vitalnext adds, using its biochemical background, ingredients that stimulate the absorption of proteins. This should result in a reduced breakdown of muscle tissue and an increased muscle mass build up. Vital01 is a powder formula and can be added to hot and cold liquids, such as milk, fruit juice, broth and yogurt. Strijker: “with five bags per day, people will get all the necessary nutrients and after five to eight weeks of use, elderly people should not only have gained body weight, but also be stronger and in better condition. ”

Vital01 is currently being tested in cooperation with Wageningen University & Research in a group of people over 65. If that study turns out well, the medical nutrition will be introduced to the market next year. The powder based formula will only be available on prescription by a doctor or dietitian.

Healthy ageing
PPM Oost-Director Marius Prins welcomes the growing number of applications of life sciences-developments in the food industry. “Food has a great impact on our lives. With our food we can combat numerous health problems. In the case of Vitalnext that is good for the growing group of elderly people, while the healthcare costs will be reduced as well with the use of medical nutrition. Treating malnourished elderly effectively will mean a huge reduction of costs worldwide. ” PPM Oost invests in Vitalnext through its revolving fund ‘Topfonds Gelderland’,. Prins: ” ‘healthy ageing ‘ and ‘quality of life ‘ are major themes. Through this investment in Vitalnext we can make a direct contribution to these themes.” PPM Oost invests in Vitalnext together with management, Galapagos NV, Van Herk Ventures, LRM NV and Hanzepoort.

Topfonds Gelderland
Topfonds Gelderland is a revolving investment fund of the province of Gelderland, managed by fund manager PPM Oost. From this fund PPM Oost invests in innovative companies and projects in the field of economics, sustainable energy supply and cultural entrepreneurship in the province of Gelderland, in cooperation with co-investors by either direct investment in enterprises or through investments in market funds. The province of Gelderland provides a total of €166,25 million, made available via Topfonds Gelderland, of which € 31 million for fund investments and €135,25 million for direct investments in companies in the province of Gelderland via subsidiary funds: Innovation and energy fund Gelderland (IEG), Fund SME credit facility Gelderland, Fund Restructuring business parks Gelderland (FHBG), Fund Leisure economy Gelderland (FGV) and Fund Cultural loans Gelderland (FGC).

PPM Oost
Participatiemaatschappij Oost Nederland NV (PPM Oost) is a regional venture capital company that is part of East Netherlands Development Agency (Oost NV). It establishes the necessary funding and its network, knowledge and skills available to entrepreneurs in High Tech, Life Tech, Cleantech & Energy and also invests in market funds. In addition, PPM Oost helps entrepreneurs to innovate, internationalize and develop (business) infrastructure.

PPM Oost stands for active management and coaching: responsibility for the society of the future. With money from the national Government and the provinces of Gelderland and Overijssel and region of Twente, PPM Oost invests in over 220 companies with a total fund of more than 300 million euros. This leads to a contribution to achieving regional, economic, environmental and employment objectives.

More information:
Vitalnext – Rein Strijker, CEO, +31 6 53 91 26 61, r.strijker@vitalnext.com, www.vitalnext.com
PPM Oost – Bart Hoeflaak, senior investment manager, + 31 6 20 30 13 13, bart.hoeflaak@ppmoost.nl, www.ppmoost.nl

Previous Post

Aptar Pharma to Exhibit Innovative Drug Delivery Devices at Pharmapack 2018 in Paris, France

Next Post

DowDuPont™ Announces Completion of DuPont’s Transactions with FMC

Related Posts

Bio-Gate and Avicanna complete first phase of development on CBD and Micro Silver BG based skin care products for global commercialization
Health & Nutrition

Bio-Gate and Avicanna complete first phase of development on CBD and Micro Silver BG based skin care products for global commercialization

30th June 2021
Good nutrition can contribute to keeping COVID-19 and other diseases away
Health & Nutrition

Good nutrition can contribute to keeping COVID-19 and other diseases away

12th October 2020
Danone Ltd invests €100m in specialized nutrition in China
Health & Nutrition

Danone Ltd invests €100m in specialized nutrition in China

20th July 2020
DuPont Nutrition & Biosciences Enters into Collaboration with Microbiome Specialist MRM Health
Health & Nutrition

DuPont Nutrition & Biosciences Enters into Collaboration with Microbiome Specialist MRM Health

25th February 2020
Herbalife Nutrition Launches Beta Heart for Better Cardiovascular Health
Health & Nutrition

Herbalife Nutrition Launches Beta Heart for Better Cardiovascular Health

24th January 2020
Royal DSM Completes Acquisition of Specialty Dairy Solutions Provider CSK
Health & Nutrition

Royal DSM Completes Acquisition of Specialty Dairy Solutions Provider CSK

7th January 2020
Next Post

DowDuPont™ Announces Completion of DuPont’s Transactions with FMC

Latest News

Envirotainer introduces the RAP for the future - part of the Releye series
Packaging & Logistic

Envirotainer introduces the RAP for the future – part of the Releye series

14th February 2022
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
Packaging & Logistic

Opticooler receives technical approval by Japanese major airlines

14th February 2022
Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease
Press Statements

Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease

14th February 2022
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Drones for Delivery To Carry Pharmaceutical Weight Forward
News

Drones for Delivery To Carry Pharmaceutical Weight Forward

9th February 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In